Want to see CMMB full AI Analyst Report?
Chemomab Therapeutics (CMMB) Stock Statistics & Valuation Metrics
Total Valuation
Chemomab Therapeutics has a market cap or net worth of $8.55M. The enterprise value is $6.28M.
- Market Cap
- $8.55M
- Enterprise Value
- $6.28M
Share Statistics
Chemomab Therapeutics has 7,200,378 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 7,200,378
- Owned by Insiders
- 0.72%
- Owned by Institutions
- 0.26%
Financial Efficiency
Chemomab Therapeutics’s return on equity (ROE) is -0.73 and return on invested capital (ROIC) is -77.57%.
- Return on Equity (ROE)
- -0.73
- Return on Assets (ROA)
- -0.65
- Return on Invested Capital (ROIC)
- -77.57%
- Return on Capital Employed (ROCE)
- -0.78
- Revenue Per Employee
- 0
- Profits Per Employee
- -749.58K
- Employee Count
- 12
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Chemomab Therapeutics is -1.20. Chemomab Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -1.20
- PS Ratio
- 0.00
- PB Ratio
- 1.13
- Price to FCF
- -0.78
- Price to Operating Cash Flow
- -0.88
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Chemomab Therapeutics had revenue of 0 and earned -8.99M in profits. Earnings per share was -1.42.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -9.57M
- Pretax Income
- -8.99M
- Net Income
- -8.99M
- EBITDA
- -9.50M
- Earnings Per Share (EPS)
- -1.42
Cash Flow
In the last 12 months, operating cash flow was -11.22M and capital expenditures -3,026, giving a free cash flow of -11.22M billion.
- Operating Cash Flow
- -11.22M
- Free Cash Flow
- -11.22M
- Free Cash Flow per Share
- -1.40
Dividends & Yields
Chemomab Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -128.08%
- Earnings Yield
- -77.23%
Stock Price Statistics
- Beta
- 1.35
- 52-Week Price Change
- -53.93%
- 50-Day Moving Average
- 1.89
- 200-Day Moving Average
- 1.76
- Relative Strength Index (RSI)
- 41.94
- Average Volume (3m)
- 99.78K
Important Dates
Chemomab Therapeutics upcoming earnings date is Nov 06, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 19, 2026
- Next Earnings Date
- Nov 06, 2026
- Ex-Dividend Date
- ―
Financial Position
Chemomab Therapeutics as a current ratio of 9.08, with Debt / Equity ratio of 0.00%
- Current Ratio
- 9.08
- Quick Ratio
- 9.08
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.80
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Chemomab Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Chemomab Therapeutics EV to EBITDA ratio is -0.35, with an EV/FCF ratio of -0.25.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.35
- EV to Free Cash Flow
- -0.25
- EV to Operating Cash Flow
- -0.25
Balance Sheet
Chemomab Therapeutics has $6.69M in cash and marketable securities with $0.00 in debt, giving a net cash position of $6.69M billion.
- Cash & Marketable Securities
- $6.69M
- Total Debt
- $0.00
- Net Cash
- $6.69M
- Net Cash Per Share
- $0.93
- Tangible Book Value Per Share
- $1.09
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Chemomab Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 56.99%
Scores
- Smart Score
- ―
- AI Score
- 42
